文献速递肝病

口服抗病毒治疗根除丙型肝炎后临床显著门静脉高压患者的临床结局与血流动力学变化

Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
PubMed 文献 · J Hepatol · 2020-06-12

这项前瞻性多中心研究纳入226例接受口服抗病毒治疗并获得持续病毒学应答的HCV相关肝硬化合并临床显著门静脉高压患者,在SVR24时存在CSPH的176例中117例于SVR96接受HVPG复测,47%HVPG<10 mmHg,53%仍存在CSPH,7%出现新发或进一步临床失代偿。

要点

  • SVR96时55/117(47%)患者HVPG<10 mmHg,53%仍存在CSPH,若假设59例未评估者均持续CSPH则为65%。
  • 高危患者(HVPG≥16 mmHg)比例从41%降至15%。
  • 17例(7%)出现新发或进一步临床失代偿,与基线HVPG≥16 mmHg和腹水史独立相关。

核心结论

  • 获得SVR的患者随访期间门静脉压力呈进行性下降,但SVR96时CSPH仍可能持续存在于53%–65%的患者中,提示失代偿风险持续存在。
  • 腹水史和高危HVPG值可识别新发或进一步临床失代偿风险较高的患者。

研究设计与样本

  • 前瞻性多中心研究,纳入226例HCV相关肝硬化合并CSPH且抗病毒治疗后获得SVR的患者。
  • SVR24时存在CSPH的患者接受SVR96时再次血流动力学评估。

主要发现

  • SVR24时176例存在CSPH,其中117例(66%)在SVR96接受HVPG测量。
  • SVR96时55/117(47%)患者HVPG<10 mmHg,53%存在CSPH(若假设全部59例未评估患者CSPH持续存在则为65%)。
  • 高危患者(HVPG≥16 mmHg)比例从41%降至15%。
  • SVR后肝硬度中位下降10.5±13 kPa,但与HVPG变化不相关(30%肝硬度测量<13.6 kPa的患者仍存在CSPH)。
  • 17例(7%)患者出现新发或进一步临床失代偿,与基线HVPG≥16 mmHg和腹水史独立相关。

关键数值与推荐

  • CSPH定义为HVPG≥10 mmHg。
  • 高危HVPG定义为HVPG≥16 mmHg。
  • SVR24时CSPH持续存在比例高达78%。

临床怎么用

  • 尽管病毒被清除,抗病毒治疗开始时存在CSPH的患者仍面临长期肝脏并发症风险,应据此进行管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Clinically significant portal hypertension (CSPH), defined as a hepatic venous pressure gradient (HVPG) ≥10 mmHg, persists 24 weeks after sustained virological response (SVR) in up to 78% of patients with HCV-related cirrhosis treated with direct-acting antivirals. These patients remain at risk of decompensation. However, long-term paired clinical and hemodynamic data are not available for this population. METHODS: We conducted a prospective multicenter study in 226 patients with HCV-related cirrhosis and CSPH who achieved SVR after antiviral therapy. Patients with CSPH 24 weeks after end of treatment (SVR24) were offered another hemodynamic assessment 96 weeks after end of treatment (SVR96). RESULTS: All patients were clinically evaluated. Out of 176 patients with CSPH at SVR24, 117 (66%) underwent an HVPG measurement at SVR96. At SVR96, 55/117 (47%) patients had HVPG <10 mmHg and 53% had CSPH (65% if we assume persistence of CSPH in all 59 non-evaluated patients). The proportion of high-risk patients (HVPG ≥16 mmHg) diminished from 41% to 15%. Liver stiffness decreased markedly after SVR (median decrease 10.5 ± 13 kPa) but did not correlate with HVPG changes (30% of patients with liver stiffness measurement <13.6 kPa still had CSPH). Seventeen (7%) patients presented with de novo/additional clinical decompensation, which was independently associated with baseline HVPG ≥16 mmHg and history of ascites. CONCLUSIONS: Patients achieving SVR experienced a progressive reduction in portal pressure during follow-up. However, CSPH may persist in up to 53-65% of patients at SVR96, indicating persistent risk of decompensation. History of ascites and high-risk HVPG values identified patients at higher risk of de novo or further clinical decompensation. LAY SUMMARY: As a major complication of cirrhosis, clinically significant portal hypertension (CSPH) is associated with adverse clinical outcomes. Herein, we show that CSPH persists at 96 weeks in just over half of patients with HCV-related cirrhosis, despite HCV elimination by direct-acting antivirals. Despite viral cure, patients with CSPH at the start of antiviral treatment remain at long-term risk of hepatic complications and should be managed accordingly.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Lens S, Baiges A, Alvarado-Tapias E, et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol. 2020. PMID: 32535060. doi:10.1016/j.jhep.2020.05.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。